|You are here: Home >> Web >>||
spinal muscular atrophy higlights from around the web.
More from the web
Research and Markets has announced the addition of the "Spinal Muscular Atrophy - Pipeline Review, H1 2014
MarketResearchReports.Biz presents this most up-to-date research on "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014". (PRWeb March 04, 2014) Read the full story at http://www.prweb.com/releases/2014/03/prweb11636722.htm
The company is looking to move its spinal muscular atrophy candidate, ISIS-SMN Rx, into phase III studies this year.
CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been in the study for over six months and are now approximately nine and a half to 16 months in age with an average age of ...
These funds were awarded as part of Families of SMA’s basic research grant program. Basic research looks into the causes of SMA, revealing new and better ways of making drugs to target the disease. (PRWeb February 21, 2014) Read the full story at http://www.prweb.com/releases/2014/02/prweb11602568.htm
Isis SNMRx shows more efficacy against now-incurable SMA.
CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). Isis also announced today that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have ...
CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of ISIS-SMNRx in children with spinal muscular atrophy (SMA). In this study, ISIS-SMNRx was well tolerated at all dose levels in children with SMA. Consistent with single-dose observations, time- and dose-dependent increases in muscle ...
Isis Pharmaceuticals' ( ISIS ) ISIS-SMN treatment appears to have increased muscle function in an ongoing multiple-dose Phase 1b/2a study of children with spinal muscular atrophy, interim results demonstrate. In addition, results from a biomarker assay show an increase of SMN protein (Survival of Motor Neuron) in the cerebral spinal fluid. The protein is particularly important for the ...
Shares of Isis Pharmaceuticals reached a new high on Friday after the company said a mid-stage trial of its experimental treatment for a rare spinal disorder showed that it increased muscle function in children. Isis is developing the drug, known as ISIS-SMN, in partnership with Biogen Idec. In addition, a recently developed biomarker test showed increases in levels of a protein critical to ...
Unable to open XML file